Cytogenetic analysis of a hemosiderotic fibrolipomatous tumor

Department of Pathology, Oregon Health & Science University, Mail code L471, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.
Cancer Genetics and Cytogenetics (Impact Factor: 1.93). 05/2008; 182(2):140-3. DOI: 10.1016/j.cancergencyto.2008.01.012
Source: PubMed


Hemosiderotic fibrolipomatous tumor is an extremely rare, nonencapsulated, fatty lesion with a consistent histologic appearance that was originally considered reactive in nature. To our knowledge, there are no previous reports on the cytogenetics of this lesion. Reported here is a case of hemosiderotic fibrolipomatous tumor arising within the subcutaneous tissue of the right foot, dorsal aspect, of an otherwise healthy 35-year-old woman. Subsequent cytogenetic analysis revealed a clonal reciprocal translocation between chromosomes 1 and 10, with a further rearrangement involving this derivative chromosome 1 and chromosome 3. This, in addition to its characteristic morphology and immunophenotype, supports the neoplastic nature of this tumor and may aid in its diagnosis.

53 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Studies on the molecular mechanisms behind soft tissue sarcoma development have disclosed that these malignancies are as genetically heterogeneous as they are clinically and morphologically diverse. Much of the genetic information on soft tissue sarcomas is still limited to the genomic level, as detected by chromosome banding analysis or comparative genomic hybridization. Based on the results of such studies, soft tissue sarcomas may be broadly dichotomized into one group, accounting for approximately 20% of the cases, characterized by specific balanced translocations, and one group typically showing massive chromosomal rearrangements leading to recurrent, but non-specific, structural and numerical rearrangements. As summarized in this review, the genomic characterization of soft tissue sarcomas has not only provided cell biologists with decisive information on the parts of the genome that may harbor genes that are essential for tumor development but also given the clinicians involved in the management of these patients a valuable diagnostic tool.
    Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin 03/2009; 456(2):129-39. DOI:10.1007/s00428-009-0736-8 · 2.65 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Myxoinflammatory fibroblastic sarcoma (MIFS) is a low-grade malignant neoplasm for which limited genetic information, including a t(1;10)(p22;q24) and amplification of chromosome 3 material, is available. To further characterize these aberrations, we have investigated eight soft tissue sarcomas diagnosed as MIFS, haemosiderotic fibrolipomatous tumour (HFT), myxoid spindle cell/pleomorphic sarcoma with MIFS features, and inflammatory malignant fibrous histiocytoma/undifferentiated pleomorphic sarcoma with prominent inflammation (IMFH) harbouring a t(1;10) or variants thereof and/or ring chromosomes with possible involvement of chromosome 3. Using chromosome banding, fluorescence in situ hybridization, array-based comparative genomic hybridization, global gene expression, and real-time quantitative PCR analyses, we identified the breakpoint regions on chromosomes 1 and 10, demonstrated and delineated the commonly amplified region on chromosome 3, and assessed the consequences of these alterations for gene expression. The breakpoints in the t(1;10) mapped to TGFBR3 in 1p22 and in or near MGEA5 in 10q24, resulting in transcriptional up-regulation of NPM3 and particularly FGF8, two consecutive genes located close to MGEA5. The ring chromosomes contained a commonly amplified 1.44 Mb region in 3p11-12, which was associated with increased expression of VGLL3 and CHMP2B. The identified genetic aberrations were not confined to MIFS; an identical t(1;10) was also found in a case of HFT and the amplicon in 3p was seen in an IMFH.
    The Journal of Pathology 04/2009; 217(5):716-27. DOI:10.1002/path.2513 · 7.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Early pleomorphic hyalinizing angiectatic tumor is a rare and recently described soft tissue lesion. Originally believed to be a precursor lesion to neoplastic pleomorphic hyalinizing angiectatic tumor, and possibly identical to hemosiderotic fibrohistiocytic lipomatous lesion/tumor, there have been recent suggestions that it is distinct from pleomorphic hyalinizing angiectatic tumor and is instead a reactive process. This article reports a case of a mass in the foot of a 45-year-old woman, which is 1 of only 15 published cases of early pleomorphic hyalinizing angiectatic tumor and is the first case to describe its radiographic appearance. Early pleomorphic hyalinizing angiectatic tumor predominantly develops in the fourth to sixth decades (average age, 45 years, range, 10-67 years). Females predominate 4 to 1. The foot/ankle is the most common site (67%). On magnetic resonance imaging (MRI), the mass appeared inhomogeneously dark on T1-weighted sequences and inhomogeneously bright on fat-suppressed T2-weighted sequences. Forty-four percent of resected lesions recur locally, but no early pleomorphic hyalinizing angiectatic tumor lesion has ever metastasized. These clinical characteristics of early pleomorphic hyalinizing angiectatic tumors closely mirror those of hemosiderotic fibrohistiocytic lipomatous lesions/tumors and are dissimilar to those for classic pleomorphic hyalinizing angiectatic tumors. Therefore, although the 3 entities share several histologic features, we believe early pleomorphic hyalinizing angiectatic tumor is equivalent to hemosiderotic fibrohistiocytic lipomatous lesion/tumor and is not a true precursor to classic pleomorphic hyalinizing angiectatic tumor.
    Orthopedics 07/2010; 33(7):516. DOI:10.3928/01477447-20100526-23 · 0.96 Impact Factor
Show more